Alembic Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 3/6
Alembic Pharmaceuticals is a dividend paying company with a current yield of 1.05% that is well covered by earnings.
Key information
1.0%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | 1.3% |
| Dividend Growth | 7.1% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | ₹11.000 |
| Payout ratio | 35% |
Recent dividend and buyback updates
Recent updates
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
Nov 10
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20Stability and Growth of Payments
Fetching dividends data
Stable Dividend: APLLTD's dividend payments have been volatile in the past 10 years.
Growing Dividend: APLLTD's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Alembic Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (APLLTD) | 1.0% |
| Market Bottom 25% (IN) | 0.2% |
| Market Top 25% (IN) | 1.1% |
| Industry Average (Pharmaceuticals) | 0.7% |
| Analyst forecast (APLLTD) (up to 3 years) | 1.3% |
Notable Dividend: APLLTD's dividend (1.05%) is higher than the bottom 25% of dividend payers in the Indian market (0.24%).
High Dividend: APLLTD's dividend (1.05%) is low compared to the top 25% of dividend payers in the Indian market (1.09%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (35.1%), APLLTD's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (266.6%), APLLTD's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 11:05 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alembic Pharmaceuticals Limited is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sarabjit Nangra | Angel Broking Private Limited |
| null null | Antique Stockbroking Ltd. |
| Vijayaraghavan Swaminathan | Avendus Spark |